Lahore: Citi Pharma Limited reported a solid financial performance for the nine months ended March 31, 2026, posting double-digit growth in profitability on the back of higher sales and improved operating earnings. The company’s board approved the unaudited financial results at its meeting held on April 29, 2026, while announcing no cash dividend, bonus shares, right shares, or any other corporate action.
During the nine-month period, Citi Pharma’s net sales climbed to Rs10.79 billion, compared with Rs10.10 billion in the corresponding period last year, reflecting steady demand for its pharmaceutical products. Gross profit also strengthened to Rs2.00 billion, up from Rs1.46 billion a year earlier, indicating improved margins despite rising costs.
The company’s operating profit increased by 40% to Rs1.65 billion, compared with Rs1.17 billion in the same period of the previous year. Despite higher administrative and selling expenses, stronger revenue generation and improved gross profitability supported the overall earnings growth.
Profit before taxation reached Rs1.35 billion, up from Rs1.03 billion in the corresponding period last year. After accounting for income tax, profit after tax rose to Rs883.44 million, representing an increase of approximately 30% from Rs678.84 million reported in the same period last year. Earnings per share (EPS) also improved to Rs3.87, compared with Rs2.97 a year earlier.
For the third quarter alone, the company posted net sales of Rs3.08 billion, while quarterly profit after tax stood at Rs275.42 million, up from Rs220.38 million recorded in the corresponding quarter of last year. Quarterly EPS improved to Rs1.21 from Rs0.96, reflecting continued earnings momentum.
On the financial position front, Citi Pharma’s total assets increased to Rs18.88 billion as of March 31, 2026, compared with Rs18.44 billion at the end of June 2025. Shareholders’ equity also strengthened to Rs10.95 billion, supported by higher retained earnings generated during the period.
The company ended the nine-month period with cash and cash equivalents of Rs321.07 million. However, operating cash flow remained negative due to higher working capital requirements, while financing activities provided support through increased short-term borrowings.
Overall, Citi Pharma delivered a robust financial performance during the first nine months of FY2026, driven by revenue growth, stronger operating margins, and higher profitability. The results reinforce the company’s steady position in Pakistan’s pharmaceutical sector while highlighting management’s focus on sustaining operational efficiency and long-term growth.
